Mefloquine increases the risk of serious psychiatric events during travel abroad: A nationwide case-control study in the Netherlands

Journal of Clinical Psychiatry

Volumn 66, Issue 2, 2005, Pages 199-204

  Van Riemsdijk, Melanie M ^a   Sturkenboom, Miriam C J M ^a   Pepplinkhuizen, Lolke ^a   Stricker, Bruno H Ch ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; MEFLOQUINE;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; COFFEE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA; MALE; MENTAL DISEASE; NETHERLANDS; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SIDE EFFECT; SMOKING; SYMPTOMATOLOGY; TRAVEL;

EID: 14644386806     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0207     Document Type: Article

References (30)

1. Monden MA, Meester WJ. Psychische decompensatie tijdens vakantie in het buitenland [Mental decompensation during vacation abroad]. Ned Tijdschr Geneeskd 1994;138:1520-1523
2. Sauteraud A, Hajjar M. Troubles psychotiques: frequence plus elevee lors des voyages en Asie [Psychotic disorders: higher incidence during travels in Asia]. Presse Med 1992;21:805-810
3. Jauhar P, Weller MP. Psychiatric morbidity and time zone changes: a study of patients from Heathrow airport. Br J Psychiatry 1982;140: 231-235
4. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45:86-91
5. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341:1299-1303
6. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996;1:485-494
7. Schlagenhauf P, Lobel H, Steffen R, et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 1997;56:235-240
8. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993;44:257-265
9. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997;315:1412-1416
10. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993;341:848-851
11. van Riemsdijk MM, Sturkenboom MCJM, Ditters JM, et al. Risk factors for neuropsychiatric adverse events and concentration impairment during the prophylactic use of mefloquine. In: Neuropsychiatric Effects of Anti-malarial Drugs [thesis]. Rotterdam, the Netherlands: Erasmus University Rotterdam; 2001
12. van Riemsdijk MM, van der Klauw MM, van Heest JA, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997;52:1-6
13. Arrindell WA, Ettema H. Dimensionele structuur, betrouwbaarheid en validiteit van de Nederlandse berwerking van de Symptom Checklist (SCL-90); gegevens gebaseerd op een fobische en een 'normale' populatie. Ned Tijdschr Psychol 1981;36:77-108
14. Koeter MWJ, Ormel J, van den Brink W. Totaalscore op de SCL-90 als maat voor de ernst van de psychopathologie. Ned Tijdschr Psychol 1988; 43:381-391
15. Huberman M, Langholz B. Application of the missing indicator method in matched case-control studies with incomplete data. Am J Epidemiol 1999;150:1340-1345
16. Hosmer D, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-456
17. Rothman K. Modern Epidemiology. Boston, Mass: Little, Brown; 1986
18. Philips M. Adverse events associated with mefloquine: women may be more susceptible to adverse events [letter]. BMJ 1996;313:1552-1553
19. Schwartz E, Potasman I, Rotenberg M, et al. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 2001;65:189-192
20. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002;58:441-445
21. van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus proguanil versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002;72:294-301
22. Overbosch D, Schilthuis H, Bienzle U, et al, and the Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travellers: results from a randomized double-blind study. Clin Infect Dis 2001;33:1015-1021
23. Landelijk Coordinatiecentrum R. Malariaprofylaxebulletin 1999. Augustus 1999
24. Lim LY, Go ML. The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol 1985;12:527-531
25. Ngiam TL, Go ML. Stereospecific inhibition of cholinesterases by mefloquine enantiomers. Chem Pharm Bull (Tokyo) 1987;35:409-412
26. Hoover DB. Cholinesterases and cholinesterase inhibitors. In: Craig CR, Stitzel RE, eds. Modern Pharmacology. 4th ed. Boston, Mass: Little, Brown; 1994:161-168
27. Gram TE. Drug absorption and distribution. In: Craig CR, Stitzel RE, eds. Modern Pharmacology. 4th ed. Boston, Mass: Little, Brown; 1994:19-32
28. Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42:415-421
29. Lucas G. Psychological aspects of travel. Travel Med Int 1990;8:99-104
30. McIntosh I. The stress of modern travel. Travel Med Int 1990;8:118-121